Related Experiment Videos
T cell co-stimulation and in vivo tolerance
1Ben May Institute, Department of Pathology and the Committee on Immunology, University of Chicago, Illinois 60637.
Current Opinion in Immunology
|October 1, 1993
Summary
Blocking CD28-B7 interactions inhibits T-cell activation and can induce T-cell anergy. However, multiple ligands complicate this co-stimulatory pathway, impacting immune responses.
Area of Science:
- Immunology
- Molecular Biology
- Cellular Biology
Background:
- Effective T-cell activation depends on T-cell receptor (TCR) and MHC-peptide engagement.
- Co-stimulation via cell surface adhesion molecules, particularly CD28, is crucial for T-cell responses.
- Blocking CD28 signaling can lead to T-cell anergy, a state of unresponsiveness.
Purpose of the Study:
- To investigate the therapeutic potential of CD28-B7 antagonists.
- To elucidate the complex regulatory mechanisms within the CD28 co-stimulatory pathway.
- To understand how multiple cross-binding ligands influence immune responses.
Main Methods:
- In vitro studies involving T-cell activation assays.
- In vivo studies using CD28-B7 antagonists in mouse models.
- Analysis of ligand interactions within the CD28-B7 pathway.
Main Results:
- Blocking CD28-B7 interactions effectively inhibits T-cell activation in vitro.
- CD28-B7 antagonists can induce T-cell clones into a state of anergy.
- The CD28 co-stimulatory pathway is complex, involving multiple cross-binding ligands.
- These ligands differentially regulate immune responses.
Conclusions:
- CD28-B7 antagonists show therapeutic potential by inhibiting T-cell activation and inducing anergy.
- The complexity of the CD28 pathway, due to multiple ligands, necessitates careful consideration for therapeutic strategies.
- Understanding these differential regulatory effects is key to harnessing CD28-targeted immunotherapies.